本文選題：替加環(huán)素注射劑 + 老年危重癥��； 參考：《中國臨床藥理學(xué)雜志》2017年14期

【摘要】：目的分析替加環(huán)素注射劑治療多重耐藥菌感染老年危重癥患者的預(yù)測因素。方法回顧性分析40例應(yīng)用替加環(huán)素治療多重耐藥菌感染老年危重癥患者的臨床資料。所有患者均予以替加環(huán)素靜脈注射,首劑100 mg,之后每次50~100 mg,q12 h,療程4~19 d。根據(jù)感染是否得到控制將治療結(jié)局分為有效組22例和無效組18例。比較2組患者的實驗室指標(biāo)、急性生理與慢性健康狀況評分Ⅱ(APACHEⅡ)、序貫器官衰竭評估(SOFA)、簡化急性生理學(xué)評分Ⅱ(SAPSⅡ)。用受試者工作特征曲線(ROC曲線)評估APACHEⅡ評分、SOFA評分和SAPSⅡ評分對替加環(huán)素療效的預(yù)測價值。結(jié)果治療前和治療后,有效組的肌酐清除率(Ccr)分別為(64.44±27.24),(71.78±30.38)mL·min~(-1),降鈣素原(PCT)分別為0.41(0.05,25.00)ng·mL~(-1)和0.13(0.05,4.00)ng·mL~(-1),差異均有統(tǒng)計學(xué)意義(均P0.05)。治療前和治療后,無效組Ccr分別為(58.34±28.18),(47.58±31.91)mL·min~(-1),APACHEⅡ評分分別為(25.06±10.18),(30.83±14.71)分,SOFA評分分別為(9.89±5.32),(12.78±5.75)分,SAPSⅡ評分分別為(60.39±20.18),(72.33±22.72)分,差異均有統(tǒng)計學(xué)意義(均P0.05)。APACHEⅡ評分、SOFA評分和SAPSⅡ評分預(yù)測替加環(huán)素治療無效的ROC曲線下面積分別為0.73,0.74和0.78,差異有統(tǒng)計學(xué)意義(均P0.05)。結(jié)論 APACHEⅡ評分、SOFA評分和SAPSⅡ評分對替加環(huán)素治療多重耐藥菌感染老年危重癥患者的療效具有一定的預(yù)測意義。
[Abstract]:Objective to analyze the predictive factors of tigicycline injection in the treatment of multidrug resistant bacteria infection. Methods the clinical data of 40 patients with multidrug resistant bacteria infection were analyzed retrospectively. All patients were treated with tegicycline intravenously, the first dose was 100 mg, and then 50 mg / kg Q12 / h for 4 days (19 days). The outcome of treatment was divided into effective group (22 cases) and ineffective group (18 cases) according to whether infection was controlled or not. The laboratory indexes, acute physiological and chronic health status score 鈪，

本文編號：1812836